Replies to post #2426 on Jaguar Health Inc (JAGX)

[TJG]

The way this has worked in the past on the Bio Tech stocks I have had is they get preliminary results then they have to clean them up by checking to ensure the results are not tainted by test results being reported wrong... and then if they like what they have they begin prepping what is needed to submit the information to the FDA... FDA will make a determination if there is more information needed or if they needed to expand something in the testing, if the FDA likes all that has been submitted and the results are all sufficient safety wise and results wise, they can begin the process of commercializing the product.

[TJG]

We are going to need to work thru those that bought yesterday and drove it up a dime... many will sell this morning knowing that the results have been pushed back... once that is done I would expect that the meat of that PR, the Thanksgiving time line and the presenting at the symposium* ... which specifically states they will go over the results... and as stated no one commits to going over results if they dont already know they are good...

SAN FRANCISCO, CA / ACCESSWIRE / October 25, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS). Napo expects to announce top line results of the trial by the Thanksgiving holiday.

Symposium: What is the simple definition of symposium?
A symposium is a conference in which experts or academics discuss a particular subject